News of Note—Flu vaccines, CureVac and more

newspaper
In this week's news of note, InvVax reported positive preclinical results for a universal flu vaccine candidate. (Pixabay)

Here is some other vaccine news of note for the week:

> About 37% of U.S. adults got a flu vaccine last year, according to the CDC. The figure represented about a 6% decline from the prior year. MarketWatch article

> CureVac started a phase 1 study of a mRNA-based rabies vaccine candidate. Release

> ImmusanT kicked off a phase 2 study of its Nexvax2 in patients with celiac disease. Release

> A report found that low vaccine confidence in Europe is contributing to a higher number of disease outbreaks. Reuters article

> Privately held biotech InvVax touted preclinical results for its universal flu vaccine candidate. Release

Suggested Articles

After years of R&D, partners Johnson & Johnson have secured European approval for their Ebola vaccine regimen.

The FDA has laid out clear efficacy requirements for a full approval, but the emergency use authorization pathway isn't so clear, an expert said.

Pfizer and its COVID-19 vaccine partner BioNTech posted positive early data for one of their four candidates in the worldwide race.